

July 30, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

(ii) SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sub: Disclosure under Regulation 30- Purchase of Assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS related to Enmetazobactam.

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, this is to inform you that Orchid Pharma Limited ("the Company") has executed the following:

- i) Entered into an agreement with the Insolvency Administrator of Allecra Therapeutics GmbH (Germany) to purchase all assets (intellectual property, trademarks, customer contracts, regulatory filings and tangible/intangible assets) of Allecra Therapeutics GmbH (Germany) subject to condition precedents being fulfilled by the parties to the agreement.
- ii) The Hon'ble Court in France in the hearing held today on July 30, 2025 has accepted our binding bid being submitted in concurrence of the Insolvency Administrator of Allecra Therapeutics SAS for the acquisition of assets including Intellectual Property Rights and Trademarks of Allecra Therapeutics SAS, on which the formal pronouncement of Order shall be made in short period of time. We are hopeful to get the order in our favour.

After the successful completion of above transactions, Orchid Pharma Limited will possess 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. This consolidation via strategic asset acquisitions will provide growth and expansion across the globe to Orchid Brand and will be financially beneficial to the company.

You are requested to take the above on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No. F10698

Encl.: as above